Fipco
@fipco.bsky.social
Just saw this. Good review on uses of apoB testing. In my view, apoB testing has a broader role than envisioned here.
jamesstein18.substack.com/p/when-lipop...
jamesstein18.substack.com/p/when-lipop...
When Lipoprotein Tests Can Be Helpful, Part I: Apolipoprotein B-100
In my first blog, I expressed skepticism about using additional blood tests for cardiovascular disease (CVD) risk prediction beyond traditional risk factors.
jamesstein18.substack.com
November 8, 2025 at 2:25 PM
Just saw this. Good review on uses of apoB testing. In my view, apoB testing has a broader role than envisioned here.
jamesstein18.substack.com/p/when-lipop...
jamesstein18.substack.com/p/when-lipop...
Also believe 10 year risk paradigm of current guidelines misses opportunity for early prevention for those with elevated longer term risk.
November 8, 2025 at 2:10 PM
Also believe 10 year risk paradigm of current guidelines misses opportunity for early prevention for those with elevated longer term risk.
Probably yes, for example lixisenatide - short half-life GLP-1ra dosed once a day was not superior to placebo on MACE (ELIXA). Real world data has some value, but results are all over the place. IMO CVOTs suggest both semaglutide and tirzepatide are good options for secondary prevention.
September 18, 2025 at 3:03 PM
Probably yes, for example lixisenatide - short half-life GLP-1ra dosed once a day was not superior to placebo on MACE (ELIXA). Real world data has some value, but results are all over the place. IMO CVOTs suggest both semaglutide and tirzepatide are good options for secondary prevention.
Key take home: current risk models understate clinical & economic benefit of long term bp/lipid lowering.
Link to slides corserahealth.com/assets/pdfs/...
Link to slides corserahealth.com/assets/pdfs/...
September 8, 2025 at 1:19 PM
Key take home: current risk models understate clinical & economic benefit of long term bp/lipid lowering.
Link to slides corserahealth.com/assets/pdfs/...
Link to slides corserahealth.com/assets/pdfs/...
Select other populations comparing PREVENT and PCE /2
• pubmed.ncbi.nlm.nih.gov/40615687/ VA-mostly male
• pubmed.ncbi.nlm.nih.gov/40560603/ Sutter
• pubmed.ncbi.nlm.nih.gov/40510258/ UK Biobank (ex-US)
• pubmed.ncbi.nlm.nih.gov/39921505/ Kaiser
• www.jacc.org/doi/10.1016/... Rochester
• pubmed.ncbi.nlm.nih.gov/40615687/ VA-mostly male
• pubmed.ncbi.nlm.nih.gov/40560603/ Sutter
• pubmed.ncbi.nlm.nih.gov/40510258/ UK Biobank (ex-US)
• pubmed.ncbi.nlm.nih.gov/39921505/ Kaiser
• www.jacc.org/doi/10.1016/... Rochester
Performance of the American Heart Association's PREVENT risk score for cardiovascular risk prediction in a multiethnic population - PubMed
The Predicting Risk of Cardiovascular EVENTS (PREVENT) equations, created and endorsed by the American Heart Association, provide cardiovascular risk estimates for the general population, but have not...
pubmed.ncbi.nlm.nih.gov
July 19, 2025 at 3:31 PM
Select other populations comparing PREVENT and PCE /2
• pubmed.ncbi.nlm.nih.gov/40615687/ VA-mostly male
• pubmed.ncbi.nlm.nih.gov/40560603/ Sutter
• pubmed.ncbi.nlm.nih.gov/40510258/ UK Biobank (ex-US)
• pubmed.ncbi.nlm.nih.gov/39921505/ Kaiser
• www.jacc.org/doi/10.1016/... Rochester
• pubmed.ncbi.nlm.nih.gov/40615687/ VA-mostly male
• pubmed.ncbi.nlm.nih.gov/40560603/ Sutter
• pubmed.ncbi.nlm.nih.gov/40510258/ UK Biobank (ex-US)
• pubmed.ncbi.nlm.nih.gov/39921505/ Kaiser
• www.jacc.org/doi/10.1016/... Rochester
